Taking Bookings for October 2024
Emgality (Galcanezumab)
Emgality (Galcanezumab): Understanding Uses and Side Effects
Emgality (Galcanezumab) is a CGRP inhibitor that is approved for the treatment of migraines. It is administered via subcutaneous injection.
​
How does Emigality (galcanezumab) work?
Galcanezumab works by blocking the action of the calcitonin gene-related peptide (CGRP), which is believed to play a role in the development of migraines. By blocking CGRP, galcanezumab can help reduce the frequency and severity of migraines.
​
What are the potential adverse effects and contraindications of Ajovy (galcanezumab)?
Cmmon adverse effects of galcanezumab may include injection site reactions, constipation, and muscle spasms. In rare cases, galcanezumab may cause serious allergic reactions, including anaphylaxis.
​
Galcanezumab should not be used in certain situations, such as during pregnancy or in people with a history of hypersensitivity reactions to the medication. It may also interact with certain medications, such as warfarin, so it's important to talk to your healthcare provider before taking Galcanezumab for migraines.
​
In addition, it's important to note that Emgality has been associated with a small increased risk of cardiovascular events, such as heart attacks and strokes. This risk appears to be highest in people with pre-existing cardiovascular disease, so it's important to discuss your cardiovascular risk factors with your healthcare provider before starting Emgality.
​
Overall, Emgality is a well-tolerated medication that has been shown to be effective in the prevention of migraines. However, as with any medication, it's important to talk to your healthcare provider about its potential adverse effects and contraindications before starting treatment.
​
What are CGRP inhibitors?
CGRP inhibitors are a class of medications that target the calcitonin gene-related peptide (CGRP), a molecule that is believed to play a role in the development of migraines. These medications work by blocking the action of CGRP or the CGRP receptor, which can help reduce the frequency and severity of migraines.
​
Who qualifies for CGRP inhibitor therapy under the PBS?
To qualify for CGRP inhibitor therapy under the PBS, patients must meet certain criteria, including:
-
A diagnosis of chronic migraine or episodic migraine with at least four migraine days per month
-
Previous failure of at least three other migraine prophylactic medications
-
A positive response to a CGRP inhibitor trial
-
Must be initially prescribed by a Neurologist
​
​
If you suffer from headaches or migraines, it's important to get advice from a qualified healthcare professional. The Headache Clinic is a specialised clinic in North Sydney that focuses on the diagnosis and management of headaches and migraines. We also serve patients all across Australia via telehealth.
​
The Headache Clinic has a team of experienced headache-specialist Neurologists who can provide expert guidance on the best treatment options for your individual needs. We understand that headaches and migraines can be really bad and we prioritise urgent appointments for those in need. We offer appointments within 1 week of booking, so you can get the care you need as soon as possible.
​
To book an appointment with one of our headache-specialist Neurologists, you can call (02) 9745 9852 or book online through our website. Our clinic is conveniently located in Sydney and offers a comfortable and welcoming environment for patients. Don't let headaches or migraines control your life – contact The Headache Clinic today to start feeling better.